Masanari Itokawa

Masanari Itokawa

Auto-generated profile, based on publicly available information

Masanari Itokawa

Tokyo Metropolitan Institute of Medical Science

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MAMakoto Arai
Makoto Arai
HYHiroko Yuzawa
Hiroko Yuzawa
INIzumi Nohara
Izumi Nohara
TOTetsuo Ohnishi
Tetsuo Ohnishi
NONanako Obata
Nanako Obata
MIMasanari Itokawa
Masanari Itokawa
Schizophrenia is a debilitating and complex mental disorder with a prevalence of approximately 1% worldwide. Its pathophysiology remains unclear, despite extensive research.1,2 Biochemical and pharmacological studies using human samples and animal models suggest that oxidative/carbonyl stress contributes to the pathophysiology of schizophrenia.3-6 Oxidative stress is a central mediator of advanced glycation end product (AGE) formation, and pyridoxamine (vitamin B6, biosynthesized from pyridoxal in vivo) is known to detoxify reactive carbonyl compounds via carbonyl-amine chemistry. Toxic reactive carbonyl compounds such as α-oxoaldehydes (eg, methylglyoxal, glyoxal, and 3-deoxyglucosone) are formed from sugars, lipids, and amino acids.7-9 Accumulation of such reactive carbonyl compounds, referred to as carbonyl stress,10 results in the modification of proteins and the eventual formation of AGEs such as pentosidine. Cellular removal of AGEs hinges largely on the activity of the zinc metalloenzyme glyoxalase I (GLO1).11 The glyoxalase detoxification system is ubiquitous in human tissues, including the brain. The GLO1 detoxification system interacts with several metabolizing cascades, and some compounds in these cascades have been reported as candidates for involvement in the etiology of schizophrenia, such as glutathione, homocysteine, and folic acid metabolites (eFigure 1, available at http://www.prit.go.jp/En/PSchizo/TSchizo/archives.html).12-19

1 March 1994 in The Lancet
Verified
Journal Article
Closed access
TAT. Arinami
T. Arinami
HHH. Hamaguchi
H. Hamaguchi
MIM. Itokawa
M. Itokawa
HEH. Enguchi
H. Enguchi
HTH. Tagaya
H. Tagaya
HSH. Shimizu
H. Shimizu

1 April 2008 in Schizophrenia Research
Verified
Journal Article
Open access
TOTsuyuka Ohtsuki
Tsuyuka Ohtsuki
MKMinori Koga
Minori Koga
HIHiroki Ishiguro
Hiroki Ishiguro
YHYasue Horiuchi
Yasue Horiuchi
MAMakoto Arai
Makoto Arai
TATadao Arinami
Tadao Arinami
Glutamate dysfunction has been implicated in the pathophysiology of schizophrenia. The metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors. GRM7, the gene that encodes mGluR7, is expressed in many regions of the human central nervous system. The GRM7 gene is located on human chromosome 3p26, which has been suggested by linkage analysis to contain a susceptibility locus for schizophrenia. We screened for mutations in all exons, exon/intron junctions, and promoter regions of the GRM7 gene in Japanese patients with schizophrenia and evaluated associations between the detected polymorphisms and schizophrenia. We examined the influence of one polymorphism associated with schizophrenia on the expression of GRM7 by dual-luciferase assay in transfected cells. Twenty-five polymorphisms/mutations were detected in GRM7. Case-control analysis revealed a potential association of a synonymous polymorphism (371T/C, rs3749380) in exon 1 with schizophrenia in our case-control study of 2293 Japanese patients with schizophrenia and 2382 Japanese control subjects (allelic p=0.009). Dual-luciferase assay revealed suppression of transcription activity by exon 1 containing this polymorphism and a statistically significant difference in the promoter activity between the T and C alleles. Our results support the possible association of a GRM7 gene polymorphism with genetic susceptibility to schizophrenia.

1 November 2011 in Schizophrenia Research
Verified
Journal Article
Closed access
LOLina Orikabe
Lina Orikabe
HYHidenori Yamasue
Hidenori Yamasue
HIHideyuki Inoue
Hideyuki Inoue
YTYoichiro Takayanagi
Yoichiro Takayanagi
YMYuriko Mozue
Yuriko Mozue
KKKiyoto Kasai
Kiyoto Kasai

23 September 2013 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
MMMitsuhiro Miyashita
Mitsuhiro Miyashita
MAMakoto Arai
Makoto Arai
AKAkiko Kobori
Akiko Kobori
TITomoe Ichikawa
Tomoe Ichikawa
KTKazuya Toriumi
Kazuya Toriumi
MIMasanari Itokawa
Masanari Itokawa
Accumulating evidence suggests that advanced glycation end products, generated as a consequence of facilitated carbonyl stress, are implicated in the development of a variety of diseases. These diseases include neurodegenerative illnesses, such as Alzheimer disease. Pyridoxamine is one of the 3 forms of vitamin B6, and it acts by combating carbonyl stress and inhibiting the formation of AGEs. Depletion of pyridoxamine due to enhanced carbonyl stress eventually leads to a decrease in the other forms of vitamin B6, namely pyridoxal and pyridoxine. We previously reported that higher levels of plasma pentosidine, a well-known biomarker for advanced glycation end products, and decreased serum pyridoxal levels were found in a subpopulation of schizophrenic patients. However, there is as yet no clinical characterization of this subset of schizophrenia. In this study, we found that these patients shared many clinical features with treatment-resistant schizophrenia. These include a higher proportion of inpatients, low educational status, longer durations of hospitalization, and higher doses of antipsychotic medication, compared with patients without carbonyl stress. Interestingly, psychopathological symptoms showed a tendency towards negative association with serum vitamin B6 levels. Our results support the idea that treatment regimes reducing carbonyl stress, such as supplementation of pyridoxamine, could provide novel therapeutic benefits for this subgroup of patients.

1 July 2015 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
YKYoussef Kouidrat
Youssef Kouidrat
AAAli Amad
Ali Amad
MAMakoto Arai
Makoto Arai
MMMitsuhiro Miyashita
Mitsuhiro Miyashita
JLJean-Daniel Lalau
Jean-Daniel Lalau
MIMasanari Itokawa
Masanari Itokawa